Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.42 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.39 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | BAX | Q07812 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646214 | 0.99 | PTPN1 (0.56) | PTPN1PTPN2GRIA2KYAT1KYAT3 | |
| Potassium SCHEMBL646530 | 0.98 | PTPN1 (0.58) | PTPN1PTPN2GRIA2KYAT1KYAT3 | |
| SCHEMBL2936979 | 0.89 | PTPN1 (0.56) | PTPN1PTPN2GRIA2KYAT1KYAT3 | |
| SCHEMBL3221987 | 0.89 | PTPN1 (0.51) | PTPN1PTPN2GRIA2FFAR1 | |
| SCHEMBL3215649 | 0.82 | PTPN1 (0.77) | PTPN1PTPN2 | |
| SCHEMBL646443 | 0.82 | PTPN1 (0.45) | PTPN1GRIA2FFAR1FFAR4MMP2 | |
| SCHEMBL3213384 | 0.81 | PTPN1 (0.50) | PTPN1PTPN2FFAR1 | |
| SCHEMBL647178 | 0.81 | PTPN1 (0.56) | PTPN1PTPN2 | |
| Potassium SCHEMBL646444 | 0.80 | PTPN1 (0.45) | PTPN1GRIA2FFAR1FFAR4 | |
| SCHEMBL4647040 | 0.80 | PTPN1 (0.50) | PTPN1GRIA2FFAR1FFAR4MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | claimed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | claimed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | claimed |
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| EP-2227245-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| EP-2089026-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009068689-A2 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008070552-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | NOVARTIS AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008067527-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | PTPN1 17/4885PTPN2 9/4885GRIA2 611/4885 |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885PTPN2 49/4885GRIA2 2084/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885PTPN2 39/4885GRIA2 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.